Ignite Creation Date:
2025-12-24 @ 10:12 PM
Ignite Modification Date:
2025-12-25 @ 7:47 PM
Study NCT ID:
NCT06415435
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-04-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
Sponsor:
Benev Company, Inc.
Organization:
Study Overview
Official Title:
A Multi-Center, Open-Label, Prospective Study of the Sylfirm X Device for the Treatment of Melasma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging.
The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.
The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: